Clinical use of a 180‐day implantable glucose sensor improves glycated haemoglobin and time in range in patients with type 1 diabetes. Issue 7 (27th February 2020)

• Record Type: Journal Article
• Authors: Irace, Concetta; Cutruzzolà, Antonio; Nuzzi, Annamaria; Assaloni, Roberta; Brunato, Barbara; Pitocco, Dario; Tartaglione, Linda; Di Molfetta, Sergio; Cignarelli, Angelo; Laviola, Luigi; Citro, Giuseppe; Lovati, Elisabetta; Gnasso, Agostino; Tweden, Katherine S; Kaufman, Francine R
• Is Part Of: Diabetes, obesity & metabolism. Volume 22:Issue 7(2020)
• Page Start: 1056
• Page End: 1061
• Publication Date: 2020-02-27
• Subjects: Diabetes -- Periodicals; Obesity -- Periodicals; Metabolism -- Disorders -- Periodicals; Clinical pharmacology -- Periodicals; 616.462
• DOI: 10.1111/dom.13993
• Languages: English
• ISSNs: 1462-8902

Abstract

Abstract: Aims: This real‐world study evaluated the changes in glycated haemoglobin (HbA1c) and continuous glucose monitoring (CGM) metrics associated with use of the implantable 180‐day Eversense CGM System (Eversense) in patients with type 1 diabetes. Materials and methods: This was a prospective, multicentre, observational study among adult participants aged ≥18 years with type 1 diabetes across seven diabetes‐care centres in Italy who had Eversense inserted for the first time. HbA1c was measured at baseline and at 180 days. Changes in time in range [TIR (glucose 70–180 mg/dL)], time above range [TAR (glucose >180 mg/dL)], time below range [TBR (glucose <70 mg/dL)] and glycaemic variability were also assessed. Data were also analysed by previous CGM use and by mode of insulin delivery. Results: One‐hundred patients were enrolled (mean age 36 ± 12 years, mean baseline HbA1c 7.4 ± 0.92% [57 ± 10 mmol/mol]). Fifty‐six per cent of patients were users of the continuous subcutaneous insulin infusion pump and 45% were previous users of CGM. HbA1c significantly decreased in patients after 180 days of sensor wear (−0.43% ± 0.69%, 5 ± 8 mmol/mol, P < 0.0001). As expected, CGM‐naïve patients achieved the greatest reduction in HbA1c (−0.74% ± 0.48%, 8 ± 5 mmol/mol). TIR significantly increased and TAR and mean daily sensor glucose significantly decreased while TBR did not change after 180 days of sensor wear. Conclusions: Real‐world clinical use of the Eversense CGM System for 180 days was associated with significant improvements in HbA1c and CGM metrics among adults with type 1 diabetes. The study is registered on clinicaltrials.gov (NCT04160156).